In human epidermal growth factor receptor 2 (HER2)-low breast cancer, paritaprevir increases ROS and LIP by preventing VDAC3-derived circular RNA from binding heat shock protein family B (small) member 1 protein, overcoming resistance to trastuzumab deruxtecan [110]. This evidence concerns the gene ERBB2 and breast carcinoma.